- Home
- FTAI vs GMAB Comparison
FTAI vs GMAB Comparison
Compare FTAI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTAI
- GMAB
- Stock Information
- Founded
- FTAI 2011
- GMAB 1999
- Country
- FTAI United States
- GMAB Denmark
- Employees
- FTAI N/A
- GMAB N/A
- Industry
- FTAI Misc Corporate Leasing Services
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FTAI Industrials
- GMAB Health Care
- Exchange
- FTAI Nasdaq
- GMAB Nasdaq
- Market Cap
- FTAI 12.9B
- GMAB 12.1B
- IPO Year
- FTAI 2015
- GMAB N/A
- Fundamental
- Price
- FTAI $129.31
- GMAB $22.34
- Analyst Decision
- FTAI Strong Buy
- GMAB Buy
- Analyst Count
- FTAI 12
- GMAB 9
- Target Price
- FTAI $167.33
- GMAB $40.71
- AVG Volume (30 Days)
- FTAI 2.7M
- GMAB 1.9M
- Earning Date
- FTAI 02-26-2025
- GMAB 02-12-2025
- Dividend Yield
- FTAI 0.92%
- GMAB N/A
- EPS Growth
- FTAI N/A
- GMAB 83.82
- EPS
- FTAI N/A
- GMAB 16.85
- Revenue
- FTAI $1,548,819,000.00
- GMAB $2,988,286,182.00
- Revenue This Year
- FTAI $52.19
- GMAB $18.78
- Revenue Next Year
- FTAI $31.71
- GMAB $14.98
- P/E Ratio
- FTAI N/A
- GMAB $13.00
- Revenue Growth
- FTAI 36.77
- GMAB 30.67
- 52 Week Low
- FTAI $54.84
- GMAB $18.64
- 52 Week High
- FTAI $181.64
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- FTAI 54.60
- GMAB 65.39
- Support Level
- FTAI $105.52
- GMAB $18.74
- Resistance Level
- FTAI $158.83
- GMAB $22.55
- Average True Range (ATR)
- FTAI 9.30
- GMAB 0.46
- MACD
- FTAI 3.99
- GMAB 0.39
- Stochastic Oscillator
- FTAI 51.87
- GMAB 94.64
About FTAI FTAI Aviation Ltd.
FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate strong and stable cash flows with the potential for earnings growth and asset appreciation.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.